Log in

NASDAQ:ALKS - Alkermes Stock Price, Forecast & News

$17.62
-0.58 (-3.19 %)
(As of 01/26/2020 11:21 AM ET)
Today's Range
$17.25
Now: $17.62
$18.46
50-Day Range
$17.62
MA: $20.09
$21.70
52-Week Range
$17.11
Now: $17.62
$37.75
Volume1.93 million shs
Average Volume1.22 million shs
Market Capitalization$2.78 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.09 billion
Cash Flow$0.60 per share
Book Value$7.54 per share

Profitability

Net Income$-139,310,000.00

Miscellaneous

Employees2,300
Market Cap$2.78 billion
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.


Alkermes (NASDAQ:ALKS) Frequently Asked Questions

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

How were Alkermes' earnings last quarter?

Alkermes Plc (NASDAQ:ALKS) issued its quarterly earnings results on Wednesday, October, 23rd. The company reported ($0.04) EPS for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.17. The company earned $255.24 million during the quarter, compared to the consensus estimate of $252.65 million. Alkermes had a negative return on equity of 6.08% and a negative net margin of 18.71%. Alkermes's revenue was up 2.6% on a year-over-year basis. During the same period last year, the business posted $0.07 earnings per share. View Alkermes' Earnings History.

When is Alkermes' next earnings date?

Alkermes is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Alkermes.

What price target have analysts set for ALKS?

8 brokers have issued twelve-month price objectives for Alkermes' stock. Their forecasts range from $20.00 to $34.00. On average, they expect Alkermes' share price to reach $25.63 in the next year. This suggests a possible upside of 45.4% from the stock's current price. View Analyst Price Targets for Alkermes.

What is the consensus analysts' recommendation for Alkermes?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.

What are Wall Street analysts saying about Alkermes stock?

Here are some recent quotes from research analysts about Alkermes stock:
  • 1. According to Zacks Investment Research, "Alkermes reported impressive third-quarter results wherein both earnings and sales beat estimates. With increasing traction of Aristada in the market, Alkermes is emerging as a leader in the treatment of schizophrenia. This year will be an important one for the company’s late-stage pipeline owing to the planned submission of the NDA for ALKS 3831 for both schizophrenia and bipolar I disorder indications. The company also expects action on the regulatory review of the recently submitted NDA for Vumerity (diroximel fumarate) for multiple sclerosis in the fourth quarter. However, Alkermes is highly dependent on manufacturing and/or royalty revenues from partners, which is a concern. Shares have underperformed the industry year to date." (1/2/2020)
  • 2. HC Wainwright analysts commented, "Valuation Our $28 price target for Alkermes is based on our sum-of-the-parts NPV valuation based on each of the company’s marketed products and pipeline assets. Our DCF model utilizes a discount rate of 13.1% based on the company’s WACC (Beta of 1.9, equity risk premium of 6.7%)." (5/31/2019)

Has Alkermes been receiving favorable news coverage?

Press coverage about ALKS stock has trended extremely negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alkermes earned a news sentiment score of -4.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Alkermes.

Are investors shorting Alkermes?

Alkermes saw a increase in short interest in December. As of December 31st, there was short interest totalling 5,250,000 shares, an increase of 10.5% from the December 15th total of 4,750,000 shares. Based on an average daily trading volume, of 1,580,000 shares, the days-to-cover ratio is presently 3.3 days. Currently, 3.4% of the shares of the stock are sold short. View Alkermes' Current Options Chain.

Who are some of Alkermes' key competitors?

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Netflix (NFLX), AbbVie (ABBV), Celgene (CELG), NVIDIA (NVDA), Alibaba Group (BABA), Starbucks (SBUX), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE) and Cisco Systems (CSCO).

Who are Alkermes' key executives?

Alkermes' management team includes the folowing people:
  • Mr. Richard F. Pops, Chairman & CEO (Age 57)
  • Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)
  • Mr. James M. Frates, Sr. VP & CFO (Age 52)
  • Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 47)
  • Dr. Craig C. Hopkinson, Sr. VP of Medicines Devel. & Medical Affairs and Chief Medical Officer (Age 51)

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a number of of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.23%), Campbell & CO Investment Adviser LLC (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), Nisa Investment Advisors LLC (0.00%) and Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.00%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, James M Frates, Mark Stejbach, Michael J Landine, Nancy Wysenski, Paul J Mitchell, Richard F Pops and Shane Cooke. View Institutional Ownership Trends for Alkermes.

Which major investors are selling Alkermes stock?

ALKS stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank and Nisa Investment Advisors LLC. Company insiders that have sold Alkermes company stock in the last year include David Joseph Gaffin, Michael J Landine, Paul J Mitchell and Richard F Pops. View Insider Buying and Selling for Alkermes.

Which major investors are buying Alkermes stock?

ALKS stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Campbell & CO Investment Adviser LLC and Loring Wolcott & Coolidge Fiduciary Advisors LLP MA. View Insider Buying and Selling for Alkermes.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $17.62.

How big of a company is Alkermes?

Alkermes has a market capitalization of $2.78 billion and generates $1.09 billion in revenue each year. The company earns $-139,310,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Alkermes employs 2,300 workers across the globe.View Additional Information About Alkermes.

What is Alkermes' official website?

The official website for Alkermes is http://www.alkermes.com/.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]


MarketBeat Community Rating for Alkermes (NASDAQ ALKS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  591 (Vote Outperform)
Underperform Votes:  437 (Vote Underperform)
Total Votes:  1,028
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel